Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Time Posted：2024-07-12 10:00
The innovative drug industry is receiving another policy boost. On July 5, the State Council executive meeting reviewed and approved the "Implementation Plan for Supporting the Development of Innovative Drugs Across the Entire Chain", marking a transition for China's domestic innovative drug industry from the research and development investment stage to the value realization stage.
Moment of Glory! The 2023 Top 100 Chinese Pharmaceutical Industry Rankings Released
Time Posted：2024-06-25 20:50
Recently, the adjustment of the 2024 National Medical Insurance Catalog was officially launched. Before this, the key tasks for the 2024 deepening of medical and health system reform were released. In addition to the first official announcement of full-chain support for innovative drugs, adjustments to the essential drug list and the expansion of high-quality volume-based procurement are imminent...
Hundreds of millions of imitations! Jiankangyuan's "Asthma Inhalation Powder" approved for market
Time Posted：2024-06-14 11:37
During the week of June 3rd to 9th, a total of 87 varieties passed/were deemed to have passed the consistency evaluation. Among them, Health Yuan's salmeterol/fluticasone propionate powder inhaler is a first-to-market drug. During the same period, 81 varieties applied for consistency evaluation.
Time Posted：2024-06-14 11:20
On June 12, 2024, Joincare Pharmaceutical Group Industry Co., Ltd. announced that it had received the Drug Registration Certificate issued by the National Medical Products Administration, marking the official approval of the marketing of its inhaled powder and mist formulation of salmeterol and fluticasone (hereinafter referred to as "the product"). This news not only brings huge market opportunities for Health and Wellness, but also provides new treatment options for relevant patients.
Time Posted：2024-06-14 11:18
Jiankangyuan recently received good news in the high-end segment of pharmaceutical R&D. Two of its key products have made key progress, demonstrating the company's strong capabilities in drug R&D and bringing new treatment options for patients.
Time Posted：2024-06-13 21:15
Recently, Lizhu Pharmaceutical Group Co., Ltd.'s wholly-owned subsidiary, Lizhu Pharmaceutical Factory (hereinafter referred to as "Lizhu Pharmaceutical"), and Xuanzhu Biotechnology Co., Ltd. (hereinafter referred to as "Xuanzhu Biotechnology"), a non-wholly-owned subsidiary of Four Rings Pharmaceutical Holdings Group Co., Ltd., jointly announced that the two parties have reached an exclusive licensing cooperation agreement on Xuanzhu Biotechnology's independently developed highly selective PDE-5 inhibitor, Vardenafil (product code: XZP-5849).
Healthy Yuan Holdings subsidiary, Lizhu Pharmaceutical: Setting sail on a new antifungal track
Time Posted：2024-06-04 19:12
Recently, Joincare Pharmaceutical Group Industry Co., Ltd.'s holding subsidiary, Lizhu Pharmaceutical Group Co., Ltd., and its wholly-owned subsidiary, Lizhu Pharmaceutical Factory (hereinafter referred to as "Lizhu Pharmaceutical"), jointly announced with Shenzhen Xianggen Bio-Technology Co., Ltd. (hereinafter referred to as "Xianggen Bio"), a company focusing on innovative drugs for antifungal infections and oral cyclic peptide innovative drug platforms, that the two parties have reached a strategic cooperation and signed a Greater China rights transaction agreement for SG1001.
Lizhu Pharmaceutical: Setting Sail on a New Antifungal Track
Time Posted：2024-06-04 16:10
Recently, Lizhu Pharmaceutical Group Co., Ltd.'s wholly-owned subsidiary, Lizhu Pharmaceutical Factory (hereinafter referred to as "Lizhu Pharmaceutical"), and Shenzhen Xianggen Bio-Technology Co., Ltd. (hereinafter referred to as "Xianggen Bio"), which focuses on innovative drugs for antifungal infections and oral cyclic peptide innovative drug platforms, jointly announced that the two parties have reached a strategic cooperation on SG1001 and signed a Greater China rights transaction agreement.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.